Form 4: Scholar Rock Holding Corp Executive Sells Shares Under 10b5-1 Plan

Jing L. Marantz, Chief Medical Officer of Scholar Rock Holding Corp, executed a sale of 2,105 shares of common stock at an average price of $30.004, while also exercising stock options to acquire 2,105 shares at $8.59, all under a pre-arranged 10b5-1 trading plan.

Summary

• Jing L. Marantz, the Chief Medical Officer of Scholar Rock Holding Corp, engaged in transactions involving the company's stock on November 11, 2024.
• Marantz exercised stock options to acquire 2,105 shares of common stock at a price of $8.59 per share.
• Simultaneously, Marantz sold 2,105 shares of common stock at a weighted average price of $30.004 per share, with individual sales ranging from $30.00 to $30.03.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on April 19, 2024.
• Following these transactions, Marantz directly owns 72,855 shares of common stock and 138,520 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-arranged trading plan. There is no indication of positive or negative sentiment from the executive's actions.

Positives

• The execution of the stock options at $8.59 indicates a potential profit for the executive.
• The sale of shares at an average of $30.004 suggests a positive market valuation at the time of the transaction.

Negatives

• The sale of 2,105 shares by a key executive could be interpreted as a lack of confidence in the company's future performance, although it is part of a pre-arranged plan.

Risks

• Executive stock sales, even under a 10b5-1 plan, can sometimes negatively impact investor sentiment.
• The market may react to the sale, potentially causing short-term price fluctuations.

Industry Context

This is a routine filing related to insider trading activity, which is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Scholar Rock.
• Similar filings are regularly seen from executives at companies like Biogen (BIIB) and Vertex Pharmaceuticals (VRTX), indicating that this type of transaction is standard practice.
• The price range of the sale ($30.00 to $30.03) is consistent with the market price of SRRK at the time of the transaction.

Stakeholder Impact

• Shareholders may react to the executive's sale of shares, although it is part of a pre-arranged plan.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

insider trading, stock options, 10b5-1 plan, executive compensation, share sale, SRRK, Scholar Rock Holding Corp